BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is reporting third quarter financial results on Thursday 5th November 2020, after market close.
According to analysts surveyed by Thomson Reuters, BMRN is expected to report 3Q20 income of $ 1.29 per share from revenue of $ 454.64 million.
For the full year, analysts anticipate top line of $ 1859.54 million, while looking forward to income of $ 4.19 per share bottom line.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 1,850.00 million ~ $ 1,950.00 million
Click Here For More Historical Outlooks Of BioMarin Pharmaceutical Inc.
Stock Performance
Shares of BioMarin Pharmaceutical Inc. traded up $ 3.76 or 5.18 percent on Wednesday, reaching $ 76.37 with volume of 2.31 million shares. BioMarin Pharmaceutical Inc. has traded high as $ 79.42 and has cracked $ 74.56 on the downward trend
The closing price of $ 76.37, representing a 6.39 % increase from the 52 week low of $ 68.25 and a 44.97 % decrease over the 52 week high of $ 131.95.
The company has a market capital of $ 13.85 billion and is part of the Healthcare sector and Biotechnology industry.
Conference Call
BioMarin Pharmaceutical Inc. will be hosting a conference call at 4:30 PM eastern time on 5th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.biomarin.com
BioMarin Pharmaceutical Inc., a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The companys commercial products also comprise Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme for adult patients with PKU; Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis IV Type A, a lysosomal storage disorder; and Firdapse for lambert eaton myasthenic syndrome.
